GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.

By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Armed with new data, GSK is preparing to file for approval of its new-generation meningitis vaccine, as it tries to maintain its leadership in the category against a challenge from Pfizer.

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.